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Abstract
Brittany M. Gallagher
SEMI-SYNTHESIS OF A NOVEL LIBRARY OF ALKALOIDS AS POTENTIAL
SELECTIVE ANALGESICS
2017-2018
Gustavo Moura-letts, Ph.D.
Master of Science in Pharmaceutical Sciences
Semi-synthetic compounds are an important part of the therapeutic drug discovery
process. The goals of the project were to synthesize different generations of matrine
analogues in order to gain many opportunities to manipulate the core structure. The longterm goal was, by manipulating the structure, the possibility to increase the biological
activity of the original compound while also decreasing the toxicity. The first-generation
matrine analogue allows for a synthesis similar to the Striker reaction producing
aminonitriles. An alkyne coupling reaction was also possible with the modification,
producing propargyl-amines. Both of the reactions resulted in the addition of a triple
bond substituent to the final products; increasing complexity and making the products not
easily metabolized in the body, therefore able reach the target of interest. The secondgeneration matrine derivative was reacted with epoxides to produce amino alcohols.
Aminonitriles, propargyl-amines, and amino alcohols are known to be backbones of
therapeutic drug compounds. The compounds synthesized were later experimented on
chronic myeloid leukemia (CML) cells, also in combination with the manufactured drug
Imatinib, in order to inhibit the BCR-ABL kinase activity in the CML cell lines E255K
and T315I.
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Chapter 1
Matrine and Matrine Analogues
Introduction
Alkaloids. Alkaloids are naturally occurring compounds produced by organisms
such as bacteria, fungi, plants and animals.1 The compounds contain basic nitrogen atoms
and have neutral to weakly acidic properties; alkaloids can contain atoms such as carbon,
hydrogen, nitrogen, oxygen, sulfur, chlorine, bromine, and phosphorous.1 The
compounds are used as starting points in drug discovery because of the wide range of
pharmacological activities including, but not limited to, antimalarial, antiasthma,
anticancer, cholinomimetic, vasodilatory, antiarrhythmic, analgesic, antibacterial, and
antihyperglycemic.1 Commonly known alkaloids include morphine, strychnine, quinine,
and ephedrine.2 Alkaloids can also have psychotropic and stimulant activities,
recreational drugs, for example, cocaine, nicotine, and caffeine.2
Medicinal plants containing alkaloids have been used as therapeutics since around
2000 BC.3 Studies on these alkaloids began around 1804 by Friedrich Sertürner, a
German chemist whom separated what he called morphium from opium.3 In German and
other European languages morphium is still the term used, however was given the name
morphine in the English and French language by the French physicist Joseph Louis GayLussac.3 French researchers Pierre Joseph Pelletier and Joseph Bienaime Caventou
discovered strychnine in the year 1818 and quinine in 1820.4 Other Alkaloids discovered
between 1817 and 1860 included xanthine, atropine, caffeine, coniine, nicotine,
colchicine, sparteine, and cocaine.4 A German chemist Albert Ladenburg, in 1886,
created the first complete synthesis of an alkaloid.4 The synthesis began by reacting 2-
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methylpyridine with acetaldehyde and then reducing the 2-propenyl pyridine product
with sodium, otherwise known as coniine.5 In the 20th century spectroscopic and
chromatographic methods were created which helped to quickly identify, by 2008, over
12,000 alkaloids.5
Matrine. Therapeutic alkaloids sophoridine, sophoranol, oxymatrine, and matrine,
as well as others, are found specifically in Sophora flavescens, which is the dried root of
the Kun Shen plant.6 Large doses of the plant root are needed in order to work, however
the root is known to have numerous of health benefits including the treatment of skin
diseases, insomnia, diarrhea, high fever, irregular heart beat, hot hands and feet, urinary
tract infection, hair loss, and Hepatitis B Virus, along with various other diseases,
infections, and symptoms.6 The alkaloid fraction of the plant root is made up of about a
twenty percent combination of oxymatrine and matrine.6 In 1998, the Institute for
Traditional Medicine introduced the fractions as a tablet under the name of Oxymatrine,
also known as White Tiger; the tablet was made available to doctors to use on patients.7
The tablet did not have any reported side effects from use.7 In a clinical setting, the
average dosage of the drug is 400-600 mg per day.7 In China, the compound is given by
injection, however, in the west, the compounds are given orally because injection
administration was not acceptable.7 The difference between receiving the medication
orally rather than through injection is the oral tablet results in more of the oxymatrine
converting to matrine, whereas the injection leads to higher levels of oxymatrine in the
blood stream; it is not clear if one delivery method is more effective than the other.8 A
capsule form has also been given and showed similar signs of the injected method.8
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According to cancer specialist Chang Minyi, “Sophora subprostrata works through
stimulating the anticancer immune mechanism of the patient and reinforcing his
resistance against the growth of the tumor.”9 Xu Xiangru and Jiang Jikai of the
Congquing University of Medical Sciences published about anticancer activity of sophora
alkaloids.9 They discussed pharmacology studies showing the alkaloids could inhibit
growth of tumor cells directly and could also affect immune functions such as turning
cancer cells into normal functioning white blood cells.9 Xiangru and Jikai also discussed,
in a clinical setting the sophora alkaloids were used successfully in treating the side effect
of the decrease of white blood cells, also known as leukopenia, caused by cancer
chemotherapy or radiation therapy, and for treating cancers such as leukemia, uterine
cervical cancer, esophageal, and laryngeal cancer.10-11
Matrine (Figure 1), as stated previously, is a tetracyclo-quinolizidine alkaloid
obtained from the Chinese sophora flavescens root.12 The herb was viewed as a mediumgrade drug where both the seeds and root are considered toxic in the China Botanical
Illustration, however the plant alkaloids have medicinal properties when used properly in
small dosages of 3-10 grams per treatment.13 The compound has been used in Chinese
medicine for thousands of years in the treatment of liver diseases, cardiovascular
diseases, asthma, and tumors.13 The drug is administered mostly through injection,
however can also be dispensed through tablet or capsule forms.
Matrine is also used as an analgesic or as a therapeutic against infection by
pathogenic microorganisms.14 It has also been used to stimulate cell metabolism and
normalize immune function.15 The mechanism of matrine is not exactly known, however,
scientists believe cell arrest, inhibition of cell proliferation, and induction of apoptosis are
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possible mechanisms for the anti-tumor activities seen in vitro and in vivo.15 The
department of Oncology at the Hospital of Traditional Medicine conducted research to
determine if using Matrine as therapy would hold anti-tumor effects on breast cancer
cells, and how exactly this happened.15 The results showed death in three different types
of cells, but there was less toxicity in the controlled cells.16 The possibility of down
regulation of IKKβ expression is the possible mechanism of action with the results shown
in western blot analysis.16
Semisynthetic approaches. Prior to chemical modification techniques being
developed, drugs were composed entirely of natural sources such as herbs, animal
products, and inorganic material.17 Centuries later, now the active components are
extracted from the natural sources, are structurally characterized, and synthesized in a
laboratory.17 The laboratory semi-synthetic and total synthetic approaches can create
more active, and higher tolerated drugs for consumers.17 Naturally derived compounds
are semi-synthesized to increase the therapeutic properties such as metabolism rate,
toxicity, and excretion.18 Anticancer compounds Topotecan and Irinotecan originate from
naturally isolated Camptothecin through commercial synthesis; the drug Vinorelbine is
produced from plant extracted Catharanthine for commercial production.18 Production of
microbes of modified alkaloids shows possibility to speed up the semi-synthesis
development of alkaloid-modified pharmaceuticals to deliver superior intermediates
closer to the final products.18
Pharmacology of Matrine. There are 27 alkaloids, which have been isolated from
the plant root; they are classified into groups including matrine-type alkaloids, cytisinetype alkaloids, anagyrine-type alkaloids, and lupinine-type alkaloids.19 The matrine-type
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alkaloids have been identified as the bioactive component contributing to
pharmacological effects on cancers, hepatitis B and C, and cardiac diseases.19 Matrine is
the most active of the alkaloids and is responsible for the antitumor, anticancer,
antimicrobial, anti-inflammatory, and analgesic properties.19-23 In the pharmaceutical
market, matrine and oxymatrine are the only two compounds required as standards of
evaluation of drug quality; no less than 1.2 percent of combined content of the two
compounds should be analyzed by HPLC.24 Over the years, TLC, HPLC, and capillary
electrophoresis have been used as methods to monitor the compounds and control the
quality isolated from the plant root.25 The type and size of the ring structure of the core
scaffold has main impact on the therapeutic properties of the compound.26 The structure
of matrine contains both a nitrogen infused ring and a beta lactam ring.27 Around 60
percent of small molecule drugs contain a nitrogen heterocycle.28-32 The nitrogen
heterocycle can be a structurally diverse component in therapeutics, as well as, hold
responsibility as an essential factor of FDA approved pharmaceuticals.33 The beta lactam
ring is seen in present day antibiotics.34 The ring results in tight bonding to the active site
inhibiting enzyme activity and resulting in cell wall development.35
Hypothesis
Can we perform molecular scaffold and functional group modifications towards
tailoring the structure-activity relationships for Matrine.37
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Results
First-generation analogue. In order to begin the experiments, the first step was
to open the lactam ring of the matrine in order to keep the core structure (Figure 2); this
produced a methyl ester derivative and also provided an activation point for the analogue
reactions. The matrine analogue reaction began with 2,940 mg of the matrine dissolved in
118.37 mL of concentrated hydrochloric acid (HCl); this reaction was refluxed for 48
hours. The solution was dried and methanolic hydrogen chloride was added to the
solution, it was then stirred at room temperature while being monitored by thin layer
chromatography (TLC, 10% methanol in dichloromethane). Hydrolysis of the compound
was not evident by TLC, infrared spectroscopy (IR), or nuclear magnetic resonance
(NMR); therefore more HCl was added and the reaction had to reflux for an additional 48
hours.
The resulting solution was dried, and rinsed with methanol three times while
being dried in between. The resulting paste residue was then suspended in minimal
isopropyl alcohol and diethyl ether was added while the reaction was vigorously stirring.
The resulting precipitate was filtered, washed with ether, and the supernatant was dried;
the process was repeated until the presentation of the matrine methyl ester was a white
solid. The end product was then confirmed by 1HNMR and
matrine’s 1HNMR and
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CNMR and compared to

CNMR spectra to ensure opening; the first generation matrine

analogue was then used as the starting material moving forward without the need to
further purify.
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Second-generation analogue. The second-generation matrine analogue was a
functional group modification in order to create a matrine derivative alcohol (Figure 3).
The resulting alcohol derivative was more stable than the methyl ester starting material,
making it easier to work with. The resulting alcohol analogue was used as the starting
material for the reactions, which produced amino alcohols in the epoxide opening
analogue library. An oven dried three-neck round bottom flask with a stir bar and reflux
condenser was flushed with argon and charged with 141.51 mL of 1M (molar), boraneTHF complex; the reaction was run under neat conditions. Matrine dihydrochloride was
then added as a solid, under argon, in portions; the flask was heated and refluxed for 48
hours. The resulting reaction was quenched with methanol, underwent acid base
extraction with HCl and NaOH, the aqueous layer was extracted with DCM and the
product was allowed to precipitate in ethyl acetate. The resulting product was then rinsed
three times with methanol and dried. The product structure was confirmed through mass
spectroscopy.
Thiomatrine. The thiomatrine compound (Figure 4) was synthesized by reacting
the Lawesson’s reagent with matrine. The reaction was refluxed in THF and the carbonyl
group was converted into the thiocarbonyl by Lawesson’s reagent.
Conclusion
Semi-synthetic reactions are an important part of the therapeutic drug discovery
process. Following the synthesis of the matrine generation analogues, many opportunities
to manipulate the core structure with the long-term goal of increasing biological activity
while decreasing toxicity were available. The first generation matrine analogue allows for
a synthesis similar to the Striker reaction to occur, as well as, an alkyne coupling
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reaction, adding triple bond substituents to the final product; this increases complexity
and produces α-aminonitriles. The second-generation matrine analogue is easier to work
with because the alcohol makes the structure less reactive than the methyl ester analogue.
The second-generation matrine derivative was reacted with epoxides in order to produce
amino alcohols. Both α-aminonitriles and amino alcohols are known to be backbones of
therapeutic drug compounds.
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Chapter 2
Strecker Reaction for Matrine Analogue Library
Introduction
Strecker reaction. Adolph Strecker coined the Strecker amino acid synthesis
(Figure 5), in 1850.38 The one pot, two-step reaction is a huge advantage; the reaction is a
simple and economical creation of racemic α-aminonitriles.39 The synthesis also saves
time and resources by avoiding the separation and purification processes, resulting in
increased percent yields of the final products.40 The components in the Strecker reaction
include an aldehyde, an amine, and cyanide.41 During the Strecker reaction, the aldehyde
is condensed with ammonia in the presence of cyanide in order to form an αaminonitrile.42 The α-aminonitrile can then used as an intermediate to further synthesize
amino acids; the basis for proteins, peptides, and pharmaceuticals.43-46 A benefit of
running the reaction, in such way, is the possibility of stereoselectivity.47 There has been
considerable interest in asymmetric synthesis for active α-aminonitriles; these are the key
building blocks in pharmaceuticals and other approaches including biocatalytic routes,
and metal catalyzed hydrogenation of enamides.48 Asymmetric approaches are more
desirable due to the use of imines followed by a nucleophilic addition of cyanide in the
presence of a chiral catalyst.49-52 In order for this direction to occur, there is the need of
another donor instead of cyanide, or an iminium system instead of an imine.53
Mechanism. The mechanism for the Strecker mechanism begins with the
carbonyl group of the aldehyde being activated by acid; ammonia then condenses with
the aldehyde to form an iminium intermediate.54 After proton exchange, water is cleaved
from the iminium ion.54 Cyanide then adds as a nucleophile to the imine carbon, creating
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an α-aminonitrile.54 In the study, the first generation matrine analogue was used in place
of ammonia.55 Using an amine instead of ammonia changed the mechanism for the
synthesis of the products.55 Formation of an imine by reacting the aldehyde with the
amine, followed by hydrocyanation is an alternate synthesis to the one pot.55
Amino nitriles in pharmacology. The number of nitrile containing
pharmaceuticals is increasing; there are over 30 drugs prescribed for a diverse range of
therapeutics.56-57 In addition, more than 20 other nitrile-containing leads are in clinical
development.56-57 The pattern of nitrile-containing pharmaceutical rise identifies the
nitrile being a desirable pharmacophore in future drug discoveries.58-59 The functionality
must be activated by an electron withdrawing group, and the electrophilic additions
shown in amino nitriles, for diabetes and osteoporosis treatment, have a reversible
electrophilic attack.58-59 In most cases, the nitrile group of these drugs is not metabolized
by

the

body

and

is

excreted

without

being

altered.60

Our Study
The objective of the first generation analogue synthesis was to produce semisynthetic amino nitriles. The study began trialing different conditions to see which was
able to work best for our components in order to produce the highest percent yield.
Beginning with 25 mg scale reactions, a 1:1 ratio was used for starting material to
aldehyde with 1 mL of cyanide (acetone cyanohydrin or hydrogen cyanide). The
reactions ran under neat conditions at room temperature in a non-inert atmosphere for 24
hours. After observations were made, more small-scale reactions ran with 1Methylpiperazine as the starting material to avoid consumption of the first generation
starting material until the reaction was optimized. The ratio of aldehyde and cyanide was
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increased to 2:3 respectfully; the laboratory had the most amount of sodium cyanide in
stock, therefore this was the cyanide of choice moving forward, and 0.75 mL of methanol
was used as the solvent. Once the reaction conditions were up to par, the reaction scale
was increased to 50 mg, still using 1-Methylpiperazine as the starting material. After the
reaction could be scaled up, the 50 mg reaction ran using the first generation matrine
analogue. Reactions were experimented, letting the aldehyde react with the starting
material for approximately 15 minutes before adding the sodium cyanide, it was
determined this factor did not influence the outcome of the reaction. Finally, the reactions
were scaled up to 100 mg with 3 mL of methanol solvent with the 1:2:3 equivalences of
starting material to aldehyde to sodium cyanide.
Results. The variable in the reaction was our aldehyde. In order to acquire a
broad-spectrum library of new compounds, both aromatic and aliphatic aldehydes were
reacted. After assessing the products, it was concluded aldehydes containing carbon
chains are more reactive in the formation of the amino nitriles. In the future we would
like to extend the scope of the library towards determining the pharmacological
properties of these scaffolds.
All of the reactions from small-scale to large-scale were monitored under thin
liquid chromatography (TLC) in a chamber of 4:1 ethyl acetate to methanol. All of the
products from the large-scale reactions were confirmed through 1HNMR and
Resulting products and yields can be observed in Table 1.
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CNMR.

Conclusion
Pharmaceutical therapeutics containing nitriles is on the rise; this creates interest
in the development of this pharmacophore in drug discovery. The information the
Strecker reaction provides in addition to the use of the first-generation matrine analogue,
holds all the benefits from the known reaction with the added benefits of using a nitrile
already known for therapeutic effects. The determination of the results for the project
concluded aldehydes containing carbon chains are more reactive in the formation of the
α-aminonitriles; the longer the carbon chain, the higher of a percent yield was obtained.
In the future, we aim to extend the scope of the library towards determining the
pharmacological properties of these scaffolds.
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Table 1
First-Generation Analogue Modification Products
R

Percent Yield

R

Percent Yield

75.9

41.9

50.4

36.7

HO

CH 3

47.6

33.1

43.7
Note. For all reactions: starting material was first-generation matrine analogue; 100
mg scale reactions; 1:2:3 eq of starting material, aldehyde, NaCN respectively; 3 mL
of methanol; room temperature for 24 hours.
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Chapter 3
Alkyne Coupling for Matrine Analogue Library
Introduction
Second-generation modification. The second-generation analogue modification
was alkyne coupling reaction; during 2001 and 2002 three groups separately reported out
results using this method.61 The synthesis is a multicomponent reaction involving an
aldehyde, amine, and alkyne, undergoes direct dehydrative condensation, and advances
using a metal catalyst.61 The reaction results in propargyl amines which are the backbone
intermediates to many other compounds, including nitrogen containing active
compounds, such as β-lactams, oxotremorine analogues, conformationally restricted
peptides, isosteres, natural products, and therapeutic drug molecules.62-64 The use of
alkynes is valuable in therapeutics because of the triple bond.64 The bond makes the
compound hard for the body to metabolize, thus the therapeutic will reach the target of
interest.65 Since alkynes are not metabolically liable, the potency of the drug intensifies,
therefore after synthesizing the alkynes with the starting material, there is potential for an
increase in the structure activity relationship (SAR) of the first-generation matrine
analogue, as well as, the original matrine compound.65
Mechanism. The alkyne coupling reaction synthesizes by the metal catalyst first
activating the alkyne to make a metal acetylide.66 The amine and aldehyde then combine
to create an imine intermediate.66 The imine then reacts with the acetylide through
nucleophilic addition to form the resulting propargylamine and the metal catalyst is
recovered.66
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Our Study
The alkyne coupling reaction was used as the foundation for the secondgeneration analogue modification. The study began with trialing different conditions to
produce the highest percent yield. The 10 mg experiments were set to run overnight with
various solvents; acetonitrile (ACN) 0.5 mL at 80oC and 55oC and 1 mL at 70oC,
tetrahydrofuran (THF) 1.50 mL at 55oC, heptanes 0.80 mL at 55oC, and toluene 1.7-2.0
mL at 95oC. Some of these small-scale reactions were synthesized in an inert atmosphere.
The first-generation matrine analogue was used as the starting material, Phenylacetylene
was used as the alkyne, and while determining the best conditions, 4-Chlorobenzaldehyde
remained as the consistent aldehyde. Published research papers lead to beginning with a
copper catalyst because copper catalyst precursors are cheap, readily available, less toxic,
and have most reactivity.66 In the beginning stages, copper(I) iodide was the consistent
catalyst. The equivalencies of the starting material, aldehyde, alkyne, and catalyst were
adjusted accordingly through interpretations made during TLC analysis (chamber 4:1
ethyl acetate to methanol) of each reaction. Various metal catalysts were trialed,
including copper(II) acetate, iron(III) oxide, and zinc iodide (ZnI2), to determine which
would help drive the reaction further.
Results. The reaction conditions used to scale up, to 50 mg, were determined to
be 1:1:2:1 equivalence of starting material, aldehyde, alkyne, and catalyst respectfully.
The solvent used moving forward was toluene (3 mL) at 100oC with zinc iodide as the
catalyst, Phenylacetylene as the consistent alkyne, and various aldehydes. Both aliphatic
(butyraldehyde and octylaldehyde getting below 10% yields) and aromatic aldehydes
were reacted, however it was determined aromatic compounds reacted further than
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aliphatic compounds. Moving forward we aim to extend the scope of the library towards
determining the pharmacological properties of these scaffolds.
All of the products from the large-scale reactions were confirmed through
1

HNMR and 13CNMR. The products and percent yields can be observed in Table 2.

Conclusion
The use of propargylamines is desirable in drug therapeutic discoveries. The use
of the triple bond makes the compound not easily metabolized and therefore able reach
the target of interest. The first-generation matrine analogue can be used as the amine
starting material in order to synthesize a library of propargylamines. The observations
made in the study concluded aromatic aldehydes are further reacted than aliphatic
aldehydes. In the future, we aim to extend the scope of the library towards determining
the pharmacological properties of these scaffolds.
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Table 2
Second-Generation Analogue Modifications
R

Percent Yield

Br

R

Percent Yield

Cl

98.2

76.4

96.2

66.5

OH

NO 2

80.3
Note. For all reactions: starting material was the first-generation matrine analogue; the
alkyne was phenylacetylene; ZnI2 catalyst; 100 mg scale reactions; 1:1:2:1 eq of
starting material, aldehyde, alkyne and catalyst respectively; 3 mL of toluene solvent;
100oC for 24 hours.

22

Chapter 4
Epoxide Opening for Matrine Analogue Library
Introduction
Epoxide. An epoxide is a highly reactive, nonpolar compound due to the ring
strain.67 The bond angles of the three atoms in the ring are similar to that of an equilateral
triangle; the carbon to oxygen sharp bonds result in the strain.67 Epoxides are beneficial
in synthesizing amino alcohols.68 These alcohols can further be reacted and used as
nucleophilic substitution, and the nitrogen infused ring can control the stereochemistry.69
A benefit to synthesizing amino alcohols is chirality, this characteristic is important
because it indicates optical activity, which can be used to determine different
enantiomers.70 Approximately 25 percent of drugs on the market are racemates of
synthetic chiral drugs.71 A downfall to racemic compounds is the two enantiomers of a
chiral drug can differ in dosage, efficacy, side effects, use, bioavailability, metabolism
rate, excretion, and toxicity.72 The single enantiomer form has the advantage of enhanced
therapeutic activity with limiting side effects and increased selectivity.73
Mechanism. In the second-generation matrine analogue, the nitrogen atom in our
secondary amine holds a lone pair of electrons.74 The lone pair makes for our starting
material to act as a nucleophile in the reaction scheme (Figure 6), to donate these
electrons to the electrophile in order to form a chemical bond.75 In the study, the
electrophile is the epoxide; the electrons attack the least substituted carbon in the epoxide
opening the ring, which allows the C-N bond to be formed in the product.76
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Our Study
During the formation of the epoxide opening analogue library, the secondgeneration matrine analogue was used as the nucleophile, to be reacted with various
epoxides in order to produce amino alcohols.77 The reactions ran on a 50 mg scale with
about 2 mL of acetonitrile. Due to the reactions not progressing enough, the solvent was
changed to 1,4-Doxane in order to raise the temperature of the reaction. The reactions ran
at 80oC (ACN) or 90oC (1,4-Dioxane) for 24 hours. The starting material was dissolved
in the 2 mL of solvent and epoxide was then added at a 1:1.5 ratio respectively. The
product was then compared to the starting material by TLC in a chamber of 4:1 ethyl
acetate to DCM.
The product was dried and then reconstituted in diethyl ether to separate
unreacted epoxide from the product. The reconstituted solution was put into a separator
funnel and a small amount of 6M hydrochloric acid (HCl) was added, this was the layer
the organic product diffused into. After shaking the separator funnel vigorously, the HCl
layer was extracted; an acid base reaction was next generated with sodium hydroxide
(NaOH) until a pH of 11 was formed, and a small amount of deionized (DI) water was
then added. The new basic solution was added into a second separator funnel and the
organic product was extracted three times with ethyl acetate. The organic layer was dried
with sodium sulfate (Na2SO4) and filtered into a round bottom through gravity filtration.
The round bottom was then dried and reconstituted with chloroform (CHCl3), transferred
to a tared vial, and then dried once more.
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Results. The results concluded there was not a difference in yields for aromatic or
aliphatic epoxides. Once our dry products were acquired, the structures were confirmed
through 1HNMR,

13

CNMR, and IR. The products and yields can be observed in Table

3.The study has produced a comprehensive library of matrine derived amino alcohols
which allows for the efficient determination of the biological profile of the corresponding
scaffold and potential development of selective therapeutics.
Conclusion
Amino alcohols are beneficial in drug therapeutics due to the chirality of the
compounds. Amino alcohols have showed potential in treating diabetes, tuberculosis, as
well as forming other antibiotics. This study has produce a comprehensive library of
matrine amine alcohols that would allow for the efficient determination of the biological
profile of the corresponding scaffold and potential development of selective therapeutics.
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Table 3
Epoxide Opening Reaction Products
Epoxide

Percent Yield

Epoxide

Percent Yield

OH

OH
O

53.8
O

43.6

F

OH
OH

46.8

42.6
Br

OH

46.3

HO

O

O

37.6

OH
OH
Cl

O

45.3

35.2

Note. For all reactions: The starting material was the second-generation matrine
analogue; 50 mg scale reactions; 1:1.5 eq of starting material to aldehyde; 2 mL of
solvent; 80oC (ACN) or 90oC (1,4-Dioxane) for 24 hours.
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Chapter 5
Matrine Analogue Library Pharmacological Results
Introduction
Chronic myelogenous leukemia. Chronic myelogenous leukemia (CML) is a form
of cancer, predominantly occurring in adults, which originates in blood-forming cells of
bone marrow.78-80 A change occurs forming the mutated BCR-ABL gene (Figure 7)
during the beginning development of the myeloid cells.81-83 The cells begin to mature and
divide without dying, crowding out other cells in the bone marrow and eventually
overflow into the blood stream.83 Acute leukemia can also occur from the change of the
CML cells.84-85 Studies are being done on CML in laboratories, and clinical trials, to
discover drugs to help fight the mutated gene and cells.86-87 Currently, Imatinib is the
main source of drug choice on the market to target the BCR-ABL gene.88 The drug is a
tyrosine kinase inhibitor (TKI), which is a class of chemotherapy medication to inhibit
enzyme tyrosine kinase.89 The form of therapy allows for target treatment of certain
cancers, decreasing the potential of damaging healthy cells to increase success.90 Studies
are being done to see if drugs, such as Imatinib, will give better results if combined with
another form of therapy such as chemotherapy, interferon, cancer vaccines, or other
potential drugs.91-93 One study showed enhanced results when combining Imatinib with
interferon; however this combination increased side effects.94 More studies are currently
running to see if the combination of dasatinib, nilotinib, cyclosporine, or
hydroxychloroquine can be more beneficial when combined with various TKIs.95-98
As stated previously, Sophora subprostrata [sophora alkaloids] work through
stimulating the anticancer immune mechanism strengthening the patients fight against the
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tumor.99 Pharmacology studies show alkaloids could inhibit growth of tumor cells
directly.101 Recent reports claim matrine has potential to make leukemia cells transform
into normal white blood cells.102 Matrine is also used as an analgesic or as a therapeutic
against infection by pathogenic microorganisms; it has also been used to stimulate cell
metabolism and normalize immune function.103 The mechanism of matrine is not exactly
known, however, scientists believe cell arrest, inhibition of cell proliferation, and
induction of apoptosis are possible for the anti-tumor activities seen in vitro and in
vivo.104
Results
The first and second-generation analogues of matrine, as well as various
compounds from the modification libraries were experimented to see if the compounds
could be identified as inhibitors on CML cells containing the E255K and T315I BCRABL mutation with decreased toxicity.105 The derived compounds were tested in
comparison and combination to drugs known to be therapeutics to CML patients such as
Imatinib.106
The MTT assay showed a decrease in CML cell activity after 24 hours at 3.2 mM
when exposed to matrine and the first-generation matrine analogue; thiomatrine had some
effects, however not up to par with the matrine and matrine analogues.107 Annexin V/PI
assay was used to confirm the results of the MTT assay; survival of the CML cells were
decreased at 4mM.108 An analogue from the first-generation analogue library, AMA3
(Figure 8), decreased the survival percentage of the CML cell survival at 40 nM and 400
µM. The second-generation matrine analogue did not increase apoptosis in the cell line.
Two compounds of the second-generation analogue library, 156 (Figure 9) and 159
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(Figure 10), were effective in the E255K cell line when combined with Imatinib.108 The
compounds decreased the capability of the T315I cells but were above the toxicity
observed in the control, NIH3T3 and Ba/F3, lines.
Western blot analysis determined the combination treatment of 156 and Imatinib
decreased the phosphorylation of Tyr412 on the BCR-ABL mutation cell lines of E255K,
however this was not observed in the T315I line; this data was consistent with flow
cytometric analysis.109
Structure activity relationship. The known compound in the study, Imatinib,
compares to the structures synthesized by all structures containing nitrogen
heterocycles.110,111 Imatinib is the main therapeutic used in patients with CML, however
the T315I cell line is resistant to the drug; this is also the cause for around 15 percent of
CML patient relapses.112-115 Matrine and the first generation matrine analogue, alone, did
not show much activity until 4 mM. Compound AMA3 did show cell death beginning at
40 nM. Aside from high concentrations of the synthesized compounds being used, the
structures combined with Imatinib were able to increase the therapeutic effects in the
cancer cell lines. Imatinib started showing some effects in P210 cell line at 1 µM, E255K
cell line at 4µM, and was completely resistant to T315I cells, as expected. Combining
Imatinib with structure 156 increased the death rate of the cancer cell lines while
allowing the healthy cells to mostly survive, however Imatinib worked better alone than
with compound 159 which was more toxic.
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Conclusion
Aside from the high concentrations tested thus far, there is potential for the
products to work on the cell lines if the concentration can be decreased. Further analysis
is needed to determine if caspase-independent apoptotic mechanism are induced due to
caspase-8 and caspase-3 activation not being detectable.
Future
Compounds throughout the analogue libraries will continue to be analyzed to find
an effective therapeutic for the T315I BCR-ABL mutated cells. The concentrations need
to be further optimized in order to decrease the concentrations of the drug molecules in
order to be considered for treatment in vivo studies.
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Figure 7. BCR-ABL mutated gene
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Experimental
4-(2-(2-hydroxy-3-(4-methoxyphenoxy)propyl)decahydro-1H,4H-pyrido[3,2,1ij][1,6]naphthyridin-1-yl)butan-1-ol. 1H NMR (400 MHz, Chloroform-d) δ 7.02 (s, 1H),
6.89 – 6.75 (m, 3H), 4.10 – 3.84 (m, 2H), 3.73 (s, 2H), 3.59 (tt, J = 6.2, 4.3 Hz, 4H), 3.26
– 3.03 (m, 3H), 3.00 – 2.68 (m, 6H), 2.57 (ddd, J = 29.9, 12.3, 4.2 Hz, 2H), 2.04 (dt, J =
13.2, 2.3 Hz, 2H), 1.98 – 1.81 (m, 5H), 1.68 (dq, J = 13.0, 4.2 Hz, 2H), 1.67 – 1.52 (m,
2H), 1.50 (tdd, J = 13.0, 6.3, 3.3 Hz, 4H), 1.48 – 1.23 (m, 10H), 1.27 – 1.12 (m, 2H). 13C
NMR (101 MHz, Chloroform-d) δ 115.48 , 115.47 , 114.56 , 71.39 , 71.09 , 66.24 , 65.49
, 64.58 , 64.49 , 64.05 , 62.31 , 62.14 , 61.97 , 57.62 , 57.51 , 57.45 , 57.25 , 57.23 , 57.15
, 57.02 , 55.68 , 54.26 , 52.47 , 51.85 , 50.33 , 46.22 , 41.88 , 41.86 , 38.94 , 37.21 , 37.19
, 37.08 , 34.87 , 32.86 , 32.69 , 32.57 , 31.36 , 29.66 , 28.65 , 28.40 , 28.20 , 28.15 , 27.96
, 27.38 , 27.20 , 26.78 , 21.58 , 21.55 , 21.45 , 21.38 , 21.32 , 21.23 , 21.08 , 20.83 , 19.64.
4-(2-(2-(4-bromophenyl)-2-hydroxyethyl)decahydro-1H,4H-pyrido[3,2,1ij][1,6]naphthyridin-1-yl)butan-1-ol. 1H NMR (400 MHz, Chloroform-d) δ 7.42 (ddd, J
= 7.9, 4.9, 2.7 Hz, 4H), 7.35 – 7.16 (m, 3H), 4.67 (dt, J = 10.8, 3.5 Hz, 1H), 3.66 – 3.44
(m, 7H), 3.30 – 3.00 (m, 6H), 2.86 – 2.63 (m, 9H), 2.62 – 2.51 (m, 2H), 2.30 – 2.19 (m,
1H), 2.07 – 1.91 (m, 4H), 1.86 (dddd, J = 18.3, 9.8, 7.8, 3.8 Hz, 8H), 1.83 – 1.63 (m, 2H),
1.68 – 1.59 (m, 2H), 1.63 – 1.50 (m, 2H), 1.48 (qd, J = 7.6, 7.0, 3.6 Hz, 8H), 1.47 – 1.27
(m, 7H), 1.22 (s, 1H), 1.31 – 1.10 (m, 3H).
2-(1-(4-hydroxybutyl)octahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-2(3H)yl)cyclohexan-1-ol.1H NMR (400 MHz, Chloroform-d) δ 3.59 (tt, J = 5.0, 2.5 Hz, 2H),
3.20 (dd, J = 13.1, 11.1 Hz, 1H), 3.08 (td, J = 9.5, 2.9 Hz, 1H), 2.84 – 2.70 (m, 2H), 2.60
(dd, J = 11.9, 4.3 Hz, 1H), 2.09 – 1.98 (m, 1H), 2.02 – 1.82 (m, 3H), 1.78 – 1.55 (m, 2H),
1.59 – 1.43 (m, 2H), 1.35 (s, 3H), 1.46 – 1.12 (m, 4H).t 13C NMR (101 MHz,
Chloroform-d) δ 64.52 , 62.12 , 57.62 , 57.51 , 51.82 , 46.24 , 41.92 , 37.26 , 32.89 ,
32.69 , 32.62 , 28.16 , 26.79 , 24.36 , 21.55 , 21.47 , 21.33 , 21.24 .
3-(1-(4-hydroxybutyl)octahydro-1H,4H-pyrido[3,2,1-ij][1,6]naphthyridin-2(3H)-yl)2,6,6-trimethylbicyclo[3.1.1]heptan-2-ol. 1H NMR (400 MHz, Chloroform-d) δ 4.08 –
3.93 (m, 1H), 3.60 (td, J = 6.2, 1.9 Hz, 6H), 3.23 (d, J = 12.1 Hz, 2H), 3.22 – 3.07 (m,
2H), 3.12 – 3.04 (m, 2H), 2.84 – 2.70 (m, 6H), 2.61 (dd, J = 11.9, 4.3 Hz, 3H), 2.14 –
1.99 (m, 4H), 2.03 – 1.90 (m, 2H), 1.94 – 1.79 (m, 8H), 1.80 – 1.39 (m, 19H), 1.43 – 1.07
(m, 22H), 0.80 (s, 1H). 13C NMR (101 MHz, Chloroform-d) δ 134.50 , 125.08 , 77.22 ,
76.98 , 72.07 , 68.39 , 64.48 , 62.11 , 57.61 , 57.50 , 51.87 , 46.21 , 44.05 , 41.85 , 39.63 ,
38.84 , 37.19 , 34.35 , 32.72 , 32.65 , 32.51 , 29.66 , 28.15 , 27.75 , 27.72 , 27.47 , 27.22 ,
27.08 , 26.78 , 26.36 , 26.12 , 26.08 , 21.54 , 21.28 , 21.22 , 20.87 , 19.84 .
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4-(2-(2-hydroxy-3-phenoxypropyl)decahydro-1H,4H-pyrido[3,2,1ij][1,6]naphthyridin-1-yl)butan-1-ol.1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.22
(m, 5H), 6.98 – 6.87 (m, 6H), 4.15 – 3.92 (m, 6H), 3.61 (ddd, J = 7.9, 6.2, 4.1 Hz, 7H),
3.29 – 3.08 (m, 5H), 2.99 (dd, J = 12.5, 10.3 Hz, 1H), 2.92 – 2.71 (m, 7H), 2.69 – 2.51
(m, 4H), 2.43 (dd, J = 13.0, 9.0 Hz, 1H), 2.28 (dd, J = 12.5, 3.7 Hz, 1H), 2.12 – 1.99 (m,
5H), 1.98 – 1.87 (m, 6H), 1.91 – 1.83 (m, 3H), 1.87 – 1.72 (m, 2H), 1.72 (dt, J = 8.5, 4.2
Hz, 2H), 1.71 – 1.53 (m, 6H), 1.51 (ddt, J = 13.8, 9.6, 5.4 Hz, 10H), 1.49 – 1.35 (m, 2H),
1.39 (s, 7H), 1.36 (s, 4H), 1.39 – 1.25 (m, 3H), 1.29 – 1.16 (m, 3H), 1.24 (s, 3H). 13C
NMR (101 MHz, Chloroform-d) δ 129.48 , 129.40 , 120.86 , 114.53 , 76.94 , 70.54 ,
70.26 , 66.12 , 65.38 , 64.58 , 64.36 , 64.04 , 62.45 , 62.22 , 62.09 , 57.59 , 57.50 , 57.48 ,
57.42 , 57.26 , 57.23 , 57.16 , 57.02 , 54.23 , 52.45 , 51.93 , 51.83 , 50.20 , 46.09 , 41.69 ,
38.94 , 37.04 , 36.99 , 34.90 , 32.84 , 32.63 , 32.59 , 32.34 , 31.29 , 29.69 , 28.60 , 28.33 ,
28.21 , 28.10 , 27.95 , 27.39 , 27.21 , 26.76 , 21.59 , 21.51 , 21.45 , 21.39 , 21.23 , 21.19 ,
21.08 , 20.80 , 19.56 .
4-(2-(2-(4-chlorophenyl)-2-hydroxyethyl)decahydro-1H,4H-pyrido[3,2,1ij][1,6]naphthyridin-1-yl)butan-1-ol. 1H NMR (400 MHz, Chloroform-d) δ 7.29 (s,
1H), 7.37 – 7.18 (m, 1H), 3.71 – 3.49 (m, 3H), 3.30 – 3.05 (m, 2H), 2.94 (s, 4H), 2.88 –
2.68 (m, 3H), 2.60 (dt, J = 11.9, 4.7 Hz, 1H), 2.10 – 1.99 (m, 1H), 1.99 – 1.82 (m, 3H),
1.80 – 1.44 (m, 5H), 1.39 (s, 1H), 1.27 (tddd, J = 27.3, 18.1, 8.2, 4.4 Hz, 4H). 13C NMR
(101 MHz, Chloroform-d) δ 128.52 , 128.44 , 127.45 , 127.13 , 77.20 , 73.84 , 68.93 ,
68.29 , 67.95 , 64.63 , 64.42 , 64.00 , 62.57 , 62.30 , 62.27 , 60.30 , 57.60 , 57.49 , 57.38 ,
57.25 , 57.20 , 56.97 , 56.89 , 52.25 , 51.85 , 51.27 , 46.14 , 41.84 , 39.16 , 37.14 , 36.79 ,
35.09 , 32.97 , 32.69 , 32.57 , 32.44 , 31.41 , 30.76 , 29.68 , 28.53 , 28.49 , 28.23 , 28.12 ,
27.93 , 27.41 , 27.17 , 26.78 , 21.52 , 21.40 , 21.28 , 21.24 , 21.21 , 20.99 , 20.94 , 19.75 .
4-(2-(3-(furan-2-ylmethoxy)-2-hydroxypropyl)decahydro-1H,4H-pyrido[3,2,1ij][1,6]naphthyridin-1-yl)butan-1-ol.1H NMR (400 MHz, Chloroform-d) δ 7.38 (s, 2H),
6.35 – 6.27 (m, 4H), 4.49 (s, 1H), 4.48 (s, 3H), 3.92 – 3.80 (m, 2H), 3.60 (dd, J = 10.9,
4.6 Hz, 5H), 3.56 – 3.37 (m, 4H), 3.12 (t, J = 13.0 Hz, 1H), 2.93 – 2.79 (m, 1H), 2.82 –
2.67 (m, 8H), 2.63 – 2.49 (m, 2H), 2.32 (dd, J = 13.1, 9.8 Hz, 1H), 2.18 – 2.06 (m, 1H),
2.05 – 1.88 (m, 14H), 1.92 – 1.78 (m, 4H), 1.64 (d, J = 10.0 Hz, 1H), 1.51 – 1.41 (m,
3H), 1.39 (s, 6H), 1.36 (d, J = 8.1 Hz, 3H), 1.33 – 1.16 (m, 3H), 0.83 (s, 1H). 13C NMR
(101 MHz, Chloroform-d) δ 151.65 , 142.89 , 142.72 , 116.34 , 110.23 , 109.55 , 109.40 ,
109.38 , 76.79 , 72.75 , 72.33 , 70.53 , 66.55 , 65.92 , 65.25 , 65.23 , 65.01 , 64.44 , 63.93
, 62.31 , 61.82 , 61.74 , 57.44 , 57.36 , 57.32 , 57.20 , 57.16 , 54.27 , 52.45 , 51.68 , 50.17
, 45.18 , 44.28 , 38.79 , 36.86 , 34.68 , 32.58 , 32.48 , 32.19 , 31.00 , 29.66 , 28.49 , 28.11
, 27.82 , 27.31 , 27.12 , 21.51 , 21.35 , 21.32 , 21.02 , 20.99 , 20.87 , 19.46 , 1.85 .
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